Edition:
United States

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

GlaxoSmithKline Pharmaceuticals Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

29 Oct 2016 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - GlaxoSmithKline Pharmaceuticals Ltd (GLAXO-IN)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

01 Nov 2016 Thomson Reuters Stock Report 11 $25.00

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) - Financial and Strategic SWOT Analysis Review

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) - Financial and Strategic SWOT Analysis Review Summary GlaxoSmithKline Pharma...

04 Oct 2016 GlobalData 49 $300.00

Wright Investors Service Comprehensive Report for Glaxosmithkline Pharmaceuticals Limited

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

23 Sep 2016 Wright Reports 65 $75.00

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) - Financial and Strategic SWOT Analysis Review

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) - Financial and Strategic SWOT Analysis Review Summary GlaxoSmithKline Pharma...

19 Sep 2016 GlobalData 50 $300.00

MOSL: GSK PHARMA 1QFY17 (Neutral)-Weak results-margin improvement is key

GSK PHARMA 1QFY17: Weak results; margin improvement is key (GLXO IN, Mkt Cap USD4.2b, CMP INR3348, TP INR3150, 6% Downside, ...

29 Jul 2016 Motilal Oswal Securities Ltd. 10 $104.00

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) - Financial and Strategic SWOT Analysis Review

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) - Financial and Strategic SWOT Analysis Review Summary GlaxoSmithKline Pharma...

09 Jun 2016 GlobalData 50 $300.00

MOSL: GSK PHARMA 4QFY16 (Neutral): Results ahead of estimates-margin improvement a positive surprise

GSK PHARMA 4QFY16: Results ahead of estimates; margin improvement a positive surprise (GLXO IN, Mkt Cap USD4.3b, CMP INR3425...

26 May 2016 Motilal Oswal Securities Ltd. 10 $92.00

Glaxosmithkline Pharma (GLXO) - Qtr. Update - Dated - May 25, 2016

GSK Pharma (Bloomberg: GLXO IN; CMP of Rs 3,425) GSK Pharma’s (GSK) Q4FY16 adjusted PAT declined 17% YoY to Rs 898 mn (4% ...

26 May 2016 Axis Capital Limited 4 $35.00

Thomson Reuters Stock Report - GlaxoSmithKline Pharmaceuticals Ltd (GLAXO-IN)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

10 May 2016 Thomson Reuters Stock Report 11 $25.00